Rolf Bjerkvig (f. 1953) is Professor for cell biology and has since the ealy 80s worked in experimental cancer biology.
Bjerkvig is Director of the Brain Tumor Research Center, located at the Department of Biomedicine. He is director of the Oncology Department at the Luxembourg Institute of Health, and has established the NORLUX Neuro-Oncology network.
Dr Bjerkvig receives major grants from the Norwegian Research Council, The Norwegian Cancer Society and the European Commission. He is on the editorial board on several international journals and is sitting in several national as well as international funding committees for cancer research in Europe. He has published more than 200 articles in scientific literature and has received a number of research prizes for his work. In 2015, Bjerkvig was awarded the King Olav V Research Prize in Cancer Research.
- 2020. Tumor-penetrating peptide for systemic targeting of Tenascin-C. Scientific Reports.
- 2020. Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects. Neuro-Oncology Advances (NOA).
- 2020. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathologica. 1-31.
- 2020. Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection. Cancers.
- 2020. AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. Nature Communications.
- 2019. Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma. Cancer Research. 2298-2313.
- 2019. Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma. Neuro-Oncology. 890-900.
- 2019. Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis. Acta neuropathologica communications. 1-19.
- 2019. Deciphering the complex role of thrombospondin-1 in glioblastoma development. Nature Communications. 1-15.
- 2019. Blood brain barrier opening and Therapeutic Effect of Free and Nanoencapsulated Cabazitaxel in an Invasive Patient-Derived Glioblastoma Model.
1987: Dr. philos. The Gade Institute of Pathology, University of Bergen
1981: M.Sc. Immunology, University of San Francisco, 1981.